-
Journal of Nuclear Cardiology :... Apr 2024
Topics: Humans; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Fluorodeoxyglucose F18
PubMed: 38460726
DOI: 10.1016/j.nuclcard.2024.101844 -
Seminars in Ultrasound, CT, and MR Oct 2021Since the clinical adoption of magnetic resonance (MR) in medical imaging, MR has proven to be a workhorse in diagnostic neuroradiology, with the ability to provide...
Since the clinical adoption of magnetic resonance (MR) in medical imaging, MR has proven to be a workhorse in diagnostic neuroradiology, with the ability to provide superb anatomic detail as well as additional functional and physiologic data, depending on the techniques utilized. Positron emission tomography/computed tomography has also shown irreplaceable diagnostic value in certain disease processes of the central nervous system by providing molecular and metabolic information through the development of numerous disease-specific PET tracers, many of which can be utilized as a diagnostic technique in and of themselves or can provide a valuable adjunct to information derived from MR. Despite these advances, many challenges still remain in neuroradiology, particularly in malignancy, neurodegenerative disease, epilepsy, and cerebrovascular disease. Through improvements in attenuation correction, motion correction, and PET detectors, combining the 2 modalities of PET and MR through simultaneous imaging has proven feasible and allows for improved spatial and temporal resolution without compromising either of the 2 individual modalities. The complementary information offered by both technologies has provided increased diagnostic accuracy in both research and many clinical applications in neuroradiology.
Topics: Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Neurodegenerative Diseases; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography
PubMed: 34537113
DOI: 10.1053/j.sult.2021.07.002 -
Journal of Child Neurology Dec 2022The purpose of this article is to explore the clinical and neuroradiologic properties of atypical teratoid/rhabdoid tumors. Data from 6 pediatric patients with... (Review)
Review
The purpose of this article is to explore the clinical and neuroradiologic properties of atypical teratoid/rhabdoid tumors. Data from 6 pediatric patients with atypical teratoid/rhabdoid tumors, which mainly contained the features of magnetic resonance imaging (MRI) and positron emission tomography (PET)/computed tomography (CT), was retrospectively analyzed. Follow-up was conducted in all patients through clinic services and/or telephone consultation. The patients included 4 males and 2 females, aged from 3.2 to 83.1 months at the initial diagnosis. All patients had MRI scans. Two patients underwent F-fluorodeoxyglucose PET/CT scintigraphy preoperatively and 4 postoperatively. All primary lesions were located in the cranial cavity and the average diameter of lesions was 37.2 mm. Cerebrospinal fluid spread on enhanced T1-weighted images were found in 2 patients. Multiple metastases were found on MRI and PET/CT scans, which were located at cranial cavity, spinal cord, lung and lymph node. The primary and metastatic lesions showed evident uptake of F-fluorodeoxyglucose. Two patients underwent total tumor removal, and 4 patients underwent subtotal removal. None of the patients received shunt surgery. Follow-up was performed in all 6 patients. One patient survived event-free 38.4 months after resection. The mean overall survival of the remaining 5 patients was 5.1 months. We identified specific PET/CT and MRI features that can facilitate the recognition of atypical teratoid/rhabdoid tumors prior to biopsy.
Topics: Child; Female; Humans; Male; Central Nervous System Neoplasms; Fluorodeoxyglucose F18; Magnetic Resonance Imaging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Referral and Consultation; Retrospective Studies; Rhabdoid Tumor; Telephone; Tomography, X-Ray Computed
PubMed: 36417494
DOI: 10.1177/08830738221129968 -
PET Clinics Jan 2020Positron emission tomography (PET) is an advanced functional imaging modality in oncology care for the diagnosis, staging, prognostication, and surveillance of numerous... (Review)
Review
Positron emission tomography (PET) is an advanced functional imaging modality in oncology care for the diagnosis, staging, prognostication, and surveillance of numerous malignancies. PET can also offer considerable advantages for target volume delineation as part of radiation treatment planning. In this review, data and clinical practice from 6 general oncology disease sites are assessed to descriptively evaluate the role of PET in target volume delineation. Also highlighted are several specific and practical utilities for PET imaging in radiation treatment planning. Publication of several ongoing prospective trials in the future may further expand the utility of PET for target delineation and patient care.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Fiducial Markers; Humans; Neoplasm Staging; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Tumor Burden
PubMed: 31735301
DOI: 10.1016/j.cpet.2019.08.002 -
Current Cardiology Reports Aug 2022Myocardial perfusion imaging (MPI) with single photon emission computed tomography (SPECT) has been the main method for assessing patients with known or suspected... (Review)
Review
PURPOSE OF THE REVIEW
Myocardial perfusion imaging (MPI) with single photon emission computed tomography (SPECT) has been the main method for assessing patients with known or suspected coronary artery disease (CAD) for decades. Based on a strong and growing evidence base, positron emission tomography (PET) MPI is increasingly favored when it is available. However, currently available PET perfusion tracers have limitations that have hampered broad utilization.
RECENT FINDINGS
F-18 flurpiridaz is a novel PET MPI agent that is nearing completion of studies necessary to obtain regulatory approval. It has unique capabilities that will facilitate further expansion of PET MPI utilization. In addition, it has characteristics that may define it as the best MPI agent to date, in terms of the potential to equalize accuracy independent of patient size, gender, complexity, or ability to perform exercise stress. The combination of excellent image quality and accurate absolute blood flow quantification hold the potential of its being an ideal precision tool for non-invasive assessment of myocardial blood flow and entire spectrum of ischemic heart disease.
Topics: Coronary Artery Disease; Humans; Myocardial Perfusion Imaging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon
PubMed: 35616882
DOI: 10.1007/s11886-022-01713-5 -
PET Clinics Oct 2020PET/computed tomography scans and PET/MR imaging have been applied in imaging tumors of the musculoskeletal system for their ability to provide information about... (Review)
Review
PET/computed tomography scans and PET/MR imaging have been applied in imaging tumors of the musculoskeletal system for their ability to provide information about metabolic activity. However, applications of these imaging modalities are now being extended to nononcologic musculoskeletal pathologies, such as osteoarthritis, rheumatoid arthritis, and osteoporosis. This article aims to explore the alternative uses of these imaging modalities in oncologic and nononcologic musculoskeletal pathologies. It also discusses the various strengths and some weaknesses that are seen in particular situations.
Topics: Humans; Magnetic Resonance Imaging; Multimodal Imaging; Musculoskeletal Diseases; Musculoskeletal System; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography
PubMed: 32888549
DOI: 10.1016/j.cpet.2020.06.005 -
Japanese Journal of Radiology Aug 2023Positron emission tomography (PET) with F-18 fluorodeoxyglucose (FDG) has been commonly used in many oncological areas. High-resolution PET permits a three-dimensional... (Review)
Review
Positron emission tomography (PET) with F-18 fluorodeoxyglucose (FDG) has been commonly used in many oncological areas. High-resolution PET permits a three-dimensional analysis of FDG distributions on various lesions in vivo, which can be applied for tissue characterization, risk analysis, and treatment monitoring after chemoradiotherapy and immunotherapy. Metabolic changes can be assessed using the tumor absolute FDG uptake as standardized uptake value (SUV) and metabolic tumor volume (MTV). In addition, tumor heterogeneity assessment can potentially estimate tumor aggressiveness and resistance to chemoradiotherapy. Attempts have been made to quantify intratumoral heterogeneity using radiomics. Recent reports have indicated the clinical feasibility of a dynamic FDG PET-computed tomography (CT) in pilot cohort studies of oncological cases. Dynamic imaging permits the assessment of temporal changes in FDG uptake after administration, which is particularly useful for differentiating pathological from physiological uptakes with high diagnostic accuracy. In addition, several new parameters have been introduced for the in vivo quantitative analysis of FDG metabolic processes. Thus, a four-dimensional FDG PET-CT is available for precise tissue characterization of various lesions. This review introduces various new techniques for the quantitative analysis of FDG distribution and glucose metabolism using a four-dimensional FDG analysis with PET-CT. This elegant study reveals the important role of tissue characterization and treatment strategies in oncology.
Topics: Humans; Positron Emission Tomography Computed Tomography; Fluorodeoxyglucose F18; Pilot Projects; Positron-Emission Tomography; Neoplasms; Medical Oncology; Radiopharmaceuticals
PubMed: 36947283
DOI: 10.1007/s11604-023-01411-4 -
Journal of Computer Assisted TomographyIncidental gallbladder lesions are common in imaging studies, although it is not always easy to discriminate benign lesions from gallbladder cancer with conventional...
OBJECTIVE
Incidental gallbladder lesions are common in imaging studies, although it is not always easy to discriminate benign lesions from gallbladder cancer with conventional imaging procedures. The present study aims to assess the capacity of positron emission tomography/computed tomography (PET/CT) with 2-[ 18 F]FDG to distinguish between benign and malignant pathology of the gallbladder, compared with conventional imaging techniques (contrast-enhanced CT or magnetic resonance imaging).
METHODS
Positron emission tomography/CT and conventional imaging studies of 53 patients with gallbladder lesions were evaluated and visually classified as benign, malignant, or inconclusive. Agreement between PET/CT and conventional imaging was determined, and imaging findings were correlated with histology or follow-up. Positron emission tomography/CT images were also analyzed semiquantitatively (SUV max and maximum tumor-to-liver ratio [TLR max ]). The presence of adenopathies and distant metastases was assessed and compared between both imaging procedures.
RESULTS
According to histology or follow-up, 33 patients (62%) had a malignant process and 20 (38%) had benign lesions. Positron emission tomography/CT and conventional imaging showed a moderate agreement ( κ = 0.59). Conventional imaging classified more studies as inconclusive compared with PET/CT (17.0% and 7.5%, respectively), although both procedures showed a similar accuracy. Malignant lesions had significantly higher SUV max and, especially, TLR max (0.89 and 2.38 [ P = 0.00028] for benign and malignant lesions, respectively). Positron emission tomography/CT identified more pathologic adenopathies and distant metastases, and patients with regional or distant spread had higher SUV max and TLR max in the gallbladder.
CONCLUSIONS
Positron emission tomography/CT is accurate to distinguish between benign and malignant pathology of the gallbladder, with a similar performance to conventional imaging procedures but with less inconclusive results. Malignant lesions present higher SUV max and TLR max values.
Topics: Humans; Positron Emission Tomography Computed Tomography; Gallbladder; Tomography, X-Ray Computed; Fluorodeoxyglucose F18; Positron-Emission Tomography; Radiopharmaceuticals
PubMed: 37184994
DOI: 10.1097/RCT.0000000000001431 -
Circulation. Cardiovascular Imaging Sep 2022
Topics: Animals; Fluorodeoxyglucose F18; Immunoglobulin G; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Swine
PubMed: 35862028
DOI: 10.1161/CIRCIMAGING.122.014314 -
Medicina Clinica Jan 2021
Topics: Fluorodeoxyglucose F18; Humans; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals
PubMed: 32620354
DOI: 10.1016/j.medcli.2020.04.019